Figure 2
Figure 2. OS and TTT in CLL patients. (A) Kaplan-Meier estimates of OS in 303 CLL patients (median OS, not reached; solid line) and TTT in 232 patients (median TTT, 5.3 years; dashed line). (B) Prognostic impact of CD49d on OS and TTT. Kaplan-Meier curves obtained by comparing OS of CLL patients according to CD49dlow (173 patients) and CD49dhigh (130 patients) expression are depicted in solid and dashed lines, respectively (P < .001, log-rank test); Kaplan-Meier curves obtained by comparing TTT of CLL patients according to CD49dlow (134 patients) and CD49dhigh (98 patients) expression are depicted in dotted and dot-dashed lines, respectively (P < .001, log-rank test).

OS and TTT in CLL patients. (A) Kaplan-Meier estimates of OS in 303 CLL patients (median OS, not reached; solid line) and TTT in 232 patients (median TTT, 5.3 years; dashed line). (B) Prognostic impact of CD49d on OS and TTT. Kaplan-Meier curves obtained by comparing OS of CLL patients according to CD49dlow (173 patients) and CD49dhigh (130 patients) expression are depicted in solid and dashed lines, respectively (P < .001, log-rank test); Kaplan-Meier curves obtained by comparing TTT of CLL patients according to CD49dlow (134 patients) and CD49dhigh (98 patients) expression are depicted in dotted and dot-dashed lines, respectively (P < .001, log-rank test).

Close Modal

or Create an Account

Close Modal
Close Modal